Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Source: BioAge Labs Reports Third Quarter 2024 Financial Results and Provides…
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement
RICHMOND, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases,…